Amesite Inc.
For the period ended Dec 31, 2025. Filed Feb 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Dec 31, 2025 · Filed Feb 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Notes to Condensed Financial Statements
Amesite, Inc.
Notes to Condensed Financial Statements (unaudited)
December 31, 2025 and 2024
Note 1 - Nature of Business
Amesite Inc. (the “Company”) was incorporated in November 2017. Amesite is a pioneering technology company specializing in the development and marketing of B2C and B2B AI-driven solutions, including its higher ed platform and healthcare app. Leveraging its proprietary AI infrastructure, Amesite offers cutting-edge applications that cater to both individual and professional needs. NurseMagic™, the company’s mobile healthcare app, streamlines creation of nursing notes and documentation tasks, enhances patient communication, and offers personalized guidance to nurses on patient care, medications, and handling challenging workplace situations.
Note 2 - Significant Accounting Policies
Basis of Presentation
The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information, and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete annual financial statements.
In the opinion of management, the condensed financial statements of the Company as of December 31, 2025 and 2024 and for the three months and six months ended December 31, 2025 and 2024 include all adjustments and accruals, consisting only of normal, recurring accrual adjustments, which are necessary for a fair presentation of the results for the interim periods. These interim results are not necessarily indicative of results for a full year.
Certain information and footnote disclosures normally included in condensed financial statements prepared in accordance with GAAP have been condensed in or omitted from this report pursuant to the rules and regulations of the SEC. These condensed financial statements should be read together with the financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended June 30, 2025.
There have been no material changes to the Company’s significant accounting policies as described in Note 2, “Significant Accounting Policies,” to the financial statements included in that Form 10-K. The Company has applied those accounting policies consistently to all periods presented herein.
Going Concern
The accompanying condensed financial statements have been prepared in accordance with generally accepted accounting principles applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.
The Company is developing its customer base and has not completed its efforts to establish a stabilized source of revenue sufficient to cover its expenses. The Company has had a history of net losses and negative cash flows from operating activities since inception and expects to continue to incur net losses and use cash in its operations in the foreseeable future.
The assessment of the Company’s ability to meet its future obligations is inherently judgmental, subjective and susceptible to change. Based on their current forecast, management believes that it may not have sufficient cash and cash equivalents to maintain the Company’s planned operations for the next twelve months following the issuance of these condensed financial statements.
The Company has considered both quantitative and qualitative factors that are known or reasonably known as of the date of these condensed financial statements are issued and concluded that there are conditions present in the aggregate that raise substantial doubt about the Company’s ability to continue as a going concern. In response to the conditions, management plans include generating cash by completing financing transactions, which may include offerings of common stock. However, these plans are subject to market conditions, and are not within the Company’s control, and therefore, cannot be deemed probable. There is no assurance that the Company will be successful in implementing their plans. As a result, the Company has concluded that management’s plans do not alleviate substantial doubt about the Company’s ability to continue as a going concern. The condensed financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty.
-7-
Use of Estimates
The preparation of condensed financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the condensed financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
Cash, Cash Equivalents, and Restricted Cash
The Company considers all investments with an original maturity of three months or less when purchased to be cash equivalents. The total amount of bank deposits (checking and savings accounts) insured by the FDIC at December 31, 2025 and June 30, 2025 was $250,000.
“Restricted Cash” in the balance sheets reflects amounts pledged as collateral for the Company’s credit card facility. As of December 31, 2025 and June 30, 2025, restricted cash totaled $100,000.
Accounts Receivable
Accounts receivable consists of customer collections held by a third party, such as a payment processor. These amounts are collected by the Company within 60 days of the related sales transactions. Accordingly, no allowance for doubtful accounts has been recorded.
Prepaid Expenses
The Company considers all items incurred for future services to be prepaid expenses. At December 31, 2025 and June 30, 2025, the Company’s prepaid expenses consisted of the following.
| December 31, | June 30, | |
|---|---|---|
| 2025 | 2025 | |
| Insurance | $128,769 | $64,091 |
| Other general and administrative | 30,388 | 30,009 |
| $159,157 | $94,100 |
Property and Equipment
Property and equipment are recorded at cost. The straight-line method is used for computing depreciation and amortization. Assets are depreciated over their estimated useful lives. The cost of leasehold improvements is depreciated (amortized) over the lesser of the length of the related leases or the estimated useful lives of the assets. Costs of maintenance and repairs are charged to expense when incurred.
| Depreciable Life - Years | |
| Furniture and fixtures | 7 years |
|---|---|
| Computer equipment and software | 5 years |
-8-
Capitalized Software Costs
The Company capitalizes costs incurred in the development of software for its customers, including the costs of the software, materials, consultants, and payroll and payroll related costs for employees incurred in developing computer software. Software development projects generally include three stages: the preliminary project stage (all costs are expensed as incurred), the application development stage (certain costs are capitalized and certain costs are expensed as incurred) and the post-implementation/operation stage (all costs are expensed as incurred). Capitalization of costs requires judgment in determining when a project has reached the application development stage, the proportion of time spent in the application development stage, and the period over which we expect to benefit from the use of that software. Once the software is placed in service, these costs are amortized on the straight-line method over the estimated useful life of the software, which is generally three years.
| December 31, | June 30, | |
|---|---|---|
| 2025 | 2025 | |
| Beginning capitalized software | $4,281,122 | $3,993,691 |
| Additions | 131,200 | 378,300 |
| Impairment | - | (90,869) |
| Ending capitalized software | 4,412,322 | 4,281,122 |
| Beginning accumulated amortization | 3,757,318 | 3,348,863 |
| Amortization expense | 115,506 | 408,455 |
| Ending accumulated amortization | 3,872,824 | 3,757,318 |
| Capitalized software - net | $539,498 | $523,804 |
Amortization expense is included as part of “Technology and content development” in the Statements of Operations. Future estimated amortization is as follows:
| 12 Months Ended | |
|---|---|
| December 31, 2026 | $260,146 |
| December 31, 2027 | 210,096 |
| December 31, 2028 | 69,256 |
| Total | $539,498 |
Revenue Recognition
The Company recognizes revenue in accordance with ASC 606,Revenue from Contracts with Customers (Topic 606). There have been no material changes to the Company’s revenue recognition policies from those disclosed in Note 2, Significant Accounting Policies, to the financial statements included in the Company’s Annual Report on Form 10-K for the year ended June 30, 2025.
As of December 31, 2025 and June 30, 2025, the balance of deferred revenue was $16,125 and $36,745, respectively, all of which is expected to be realized within 12 months.
The following table shows revenue from contracts with customers by customer type for the six months ended December 31, 2025 and 2024, respectively.
| For the three months ended · For the Six Months Ended | ||||
|---|---|---|---|---|
| December 31, | December 31, | |||
| Customer Type | 2025 | 2024 | 2025 | 2024 |
| Individuals (B2C) | $23,814 | $517 | $53,335 | $517 |
| Business (B2B) | 84,236 | 12,243 | 149,011 | 23,493 |
| $108,050 | $12,760 | $202,346 | $24,010 | |
-9-
Reclassifications
Certain prior period amounts have been reclassified to conform with the current period presentation.
Earnings (Loss) per Share
At December 31, 2025 and June 30, 2025, the Company had 589,038 and 601,538, respectively, potentially dilutive shares of common stock related to common stock options and warrants as determined using the if-converted method. Additionally, there were restricted stock units and deferred stock units outstanding to Board members representing potentially dilutive shares totaling 400,179 and 355,295 at December 31, 2025 and June 30, 2025, respectively. For the three months and six months ended December 31, 2025 and 2024, the dilutive effect of common stock has not been included in the average shares outstanding for the calculation of net loss per share as the effect would be anti-dilutive as a result of our net losses in these periods.
Subsequent Events
The Company evaluated subsequent events through the date this Form 10-Q was filed and has determined that no events have occurred that would require recognition or disclosure in the condensed financial statements.
Risks and Uncertainties
The Company operates in an industry subject to rapid change. The Company’s operations will be subject to significant risk and uncertainties including financial, operational, technological, and other risks associated with an early-stage company, including the potential risk of business failure.
Significant Concentrations and Risks
Assets that potentially subject the Company to significant concentration of credit risk primarily consist of cash, cash equivalents, and restricted cash. As of December 31, 2025 and June 30, 2025, all of the Company’s cash, cash equivalents, and restricted cash were deposited in financial institutions located in the United States, which management believes are of high credit quality.
During the three months and six months ended December 31, 2025, one customer accounted for 11% and 11% of the Company’s revenues, respectively. During the three months and six months ended December 31, 2024, one customer accounted for 90% and 95% of the Company’s revenues, respectively.
Recently Issued Accounting Standards
The Company has evaluated recently issued accounting pronouncements and has determined that none of the new or recently adopted standards issued by the Financial Accounting Standards Board (FASB) are expected to have a material impact on its financial statements or related disclosures.
-10-
Note 3 - Stock-Based Compensation
The Company’s Equity Incentive Plan (the “Plan”) permits the grant of stock options, stock appreciation rights, restricted stock, restricted stock units, and deferred stock units to officers, employees, directors, consultants, agents, and independent contractors of the Company. The Company believes that such awards align the interests of its employees, directors, and consultants with those of its stockholders.
Options
No options were granted for the six months ended December 31, 2025 or 2024. As of December 31, 2025, there were approximately $271,657 of total unrecognized compensation costs for employees and non-employees related to nonvested options. These costs are expected to be recognized through May 2029.
A summary of options terminated, as well as those that vested, during the three months ended December 31, 2025 is presented below:
| Options | Number of Shares | Weighted Average Exercise Price | Weighted Average Remaining Contractual Term (in years) |
|---|---|---|---|
| Outstanding at October 1, 2025 | 166,352 | $22.26 | 4.4 |
| Terminated/Expired | - | - | - |
| Additional vesting | - | - | - |
| Outstanding and vested at December 31, 2025 | 166,352 | $22.26 | 4.2 |
A summary of options terminated, as well as those that vested, during the six months ended December 31, 2025 is presented below:
| Options | Number of Shares | Weighted Average Exercise Price | Weighted Average Remaining Contractual Term (in years) |
|---|---|---|---|
| Outstanding at July 1, 2025 | 172,477 | $21.08 | 4.9 |
| Terminated/Expired | (6,125) | 2.32 | 7.4 |
| Additional vesting | - | - | - |
| Outstanding and vested at December 31, 2025 | 166,352 | $22.26 | 4.2 |
A summary of options terminated, as well as those that vested, during the three months ended December 31, 2024 is presented below:
| Options | Number of Shares | Weighted Average Exercise Price | Weighted Average Remaining Contractual Term (in years) |
|---|---|---|---|
| Outstanding at October 1, 2024 | 238,796 | $20.96 | 5.3 |
| Terminated/Expired | - | - | - |
| Additional vesting | 2,332 | 8.9 | |
| Outstanding and vested at December 31, 2024 | 241,128 | $20.76 | 5.1 |
-11-
A summary of options terminated, as well as those that vested, during the six months ended December 31, 2024 is presented below:
| Options | Number of Shares | Weighted Average Exercise Price | Weighted Average Remaining Contractual Term (in years) |
|---|---|---|---|
| Outstanding at July 1, 2024 | 235,219 | $22.05 | 5.5 |
| Terminated/Expired | - | - | - |
| Additional vesting | 5,909 | 5.53 | 8.3 |
| Outstanding and vested at December 31, 2024 | 241,128 | $20.76 | 5.1 |
Warrants
A summary of warrant activity during the three months and six months ended December 31, 2025 is presented below:
| Warrants | Number of Shares | Weighted Average Exercise Price | Weighted Average Remaining Contractual Term (in years) |
|---|---|---|---|
| Outstanding at July 1, 2025 | 429,061 | $11.03 | 2.7 |
| Expired | (12,500) | 72.00 | - |
| Additional issuances | - | - | - |
| Outstanding at September 30, 2025 | 416,561 | 9.20 | 2.4 |
| Expired | - | - | - |
| Additional issuances | - | - | - |
| Outstanding and vested at December 31, 2025 | 416,561 | $9.20 | 2.2 |
A summary of warrant activity during the three months and six months ended December 31, 2024 is presented below:
| Warrants | Number of Shares | Weighted Average Exercise Price | Weighted Average Remaining Contractual Term (in years) |
|---|---|---|---|
| Outstanding at July 1, 2024 | 397,781 | $12.85 | 3.6 |
| Expired | - | - | - |
| Additional issuances | - | - | - |
| Outstanding at September 30, 2024 | 397,781 | 12.85 | 3.4 |
| Expired | (13,783) | (24.00) | |
| Additional issuances | - | - | |
| Outstanding and vested at December 31, 2024 | 383,998 | $11.88 | 3.1 |
-12-
Board of Directors: Deferred Stock Units and Restricted Stock Units
For the six months ended December 31, 2025, $104,750 in deferred stock units were awarded. For the six months ended December 31, 2024, $101,000 in deferred stock units were awarded and $35,765 in cash compensation was accrued.
A summary of deferred stock units terminated/settled, as well as those that vested, during the six months ended December 31, 2025 and 2024 is presented below:
| Weighted Average | ||
|---|---|---|
| Number of | Exercise | |
| Shares | Price | |
| Outstanding July 1, 2025 | 190,007 | $2.84 |
| Issued | 44,884 | 2.33 |
| Terminated/Settled | - | - |
| Outstanding December 31, 2025 | 234,891 | $2.74 |
| Outstanding July 1, 2024 | 207,342 | $3.64 |
| Issued | 33,615 | 3.00 |
| Terminated/Settled | - | - |
| Outstanding December 31, 2024 | 240,957 | $3.55 |
Note: the weighed average remaining contractual term is not applicable since these do not vest until the director leaves service.
As of December 31, 2025, the Company has 326,684 shares of common stock available for granting under the Plan.
On September 29, 2021, the Board instituted annual restricted stock units (RSU) for directors in the amount of $100,000 per director. These restricted stock units vest on their one year anniversary if the director served the entire year. During the fiscal year ended June 30, 2025, the Company issued the vested RSUs from 2022 and 2024. The calendar year 2023 RSUs were not formally granted so common stock was issued under similar terms to the directors in fiscal year ended June 30, 2025.
A summary of restricted stock units terminated, as well as those that vested, during the six months ended December 31, 2025 and 2024 is presented below:
| Weighted Average · Weighted | |||
|---|---|---|---|
| Number of | Exercise | Average | |
| Shares | Price | Term (Yrs) | |
| Outstanding, July 1, 2025 | 165,288 | $2.42 | 0.68 |
| Issued | - | - | 0.00 |
| Settled | - | - | 0.00 |
| Outstanding, December 31, 2025 | 165,288 | $2.42 | 0.18 |
| Outstanding, July 1, 2024 | 307,500 | $3.90 | 0.00 |
| Issued | - | - | 0.00 |
| Settled | - | - | 0.00 |
| Outstanding, December 31, 2024 | 307,500 | $3.90 | 0.00 |
-13-
Note 4 - Income Taxes
For the six months ended December 31, 2025 and prior periods since inception, the Company’s activities have not generated taxable income or tax liabilities. The provision (benefit) for income taxes for the six months ended December 31, 2025 and 2024 assumes a 21% effective tax rate for federal income taxes and a 6% effective tax rate for state income tax purposes.
The Company has approximately $41.6 million of net operating loss carryforwards for federal and state, available to reduce future income taxes at December 31, 2025. Approximately $17,000 of the federal net operating losses will expire in 2037 and the balance can be utilized indefinitely. Due to uncertainty as to the realization of the net operating loss carryforwards and other deferred tax assets as a result of the Company’s limited operating history and operating losses since inception, a full valuation allowance has been recorded against the Company’s deferred tax assets. Accordingly, the Company has not recognized an income tax benefit on the Condensed Statements of Operations for the six months ended December 31, 2025 and 2024.
Note 5 - Segment Information
Information about reported segment revenue, segment net income (loss), and significant segment expenses is shown as follows:
| For the three months ended · For the Six Months Ended | ||||
|---|---|---|---|---|
| December 31, | December 31, | |||
| 2025 | 2024 | 2025 | 2024 | |
| Net revenue | $108,050 | $12,760 | $202,346 | $24,010 |
| Less: | ||||
| Advertising and marketing expenses | 42,561 | 41,109 | 89,027 | 114,424 |
| Capitalized software, net of amortization | 17,803 | 41,998 | (15,694) | 5,937 |
| Professional fees | 118,065 | 227,897 | 200,225 | 354,868 |
| Personnel-related expenses | 426,460 | 462,550 | 837,360 | 928,269 |
| Director restricted stock unit expense | 100,000 | 150,000 | 200,000 | 300,000 |
| Stock-based compensation expense | 72,252 | 40,995 | 144,504 | 106,435 |
| Technology and development expense | 22,653 | 18,450 | 38,775 | 36,088 |
| Depreciation | 6,337 | 6,337 | 12,674 | 12,674 |
| Other segment items (1) | 47,173 | 154,293 | 102,852 | 223,528 |
| Interest income | (12,705) | (9,232) | (32,563) | (28,531) |
| Segment net loss | $(732,548) | $(1,121,637) | $(1,374,814) | $(2,029,682) |
| Total net loss | $(732,548) | $(1,121,637) | $(1,374,814) | $(2,029,682) |
| (1) | Other segment items included in segment net income are primarily business insurance and franchise taxes as well as general office expenses. |
-14-
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.